The purpose of clinical decision support tools and systems is to provide accurate, timely information to the clinical team and patient to help inform about a patient’s care. Clinical decision support can potentially lower costs, improve patient outcomes and efficiency, and reduce patient inconvenience. In this session, we will hear from representatives from major healthcare organizations about their perspectives and experiences when adopting/implementing clinical decision support.
Chris is a strategic advisor to QIAGEN following the acquisition of N-of-One in 2019. Previously, Chris served as the Chairperson and Chief Executive Officer of N-of-One from 2012- 2019 where she led the transformation of N-of-One’s patient concierge business to a leading molecular decision support company in oncology. Under her leadership she raised capital, created the digital strategy for interpreting molecular diagnostic tests and led the strategic process resulting in a successful sale to QIAGEN in 2019. Prior to joining N-of-One, Chris was the Vice President of Clinical Analytics for Optum responsible for clinical EHR solutions. Prior to joining Optum through the acquisition of Picis in 2010, Chris was the President and COO for Picis, Inc., a global leader in the Healthcare IT market, offering digital EHR solutions to automate the clinical and revenue cycle workflows for the high acuity operations of hospitals. Previous to Picis, Chris was held leadership positions at Harte Hanks and Lightbridge. From 1994- 2001, Chris held technology roles at Lotus as Chief Information Officer and at IBM where she was Vice President of Global Business Transformation responsible for the order to cash operations and for the Information Technology/CIO function for the IBM's $8B software business. Chris currently serves a member of the Board of Directors for CareDx, Inc. a leading precision medicine company focused on high value solutions for transplant patients and caregivers. She has also provided technology expertise to three public boards including Stride Rite, GTECH, and BJ’s Wholesale group and has been a director for Emerson Hospital. Chris holds a B.S in Business Administration from the University of Massachusetts, an MA in Economics from Northeastern University and has attended MIT ‘s Executive Education Program.
Dr. Shaw is executive director of the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (Khalifa Institute). She joined The University of Texas MD Anderson Cancer Center in 2013, bringing an extensive background in science leadership and education. Prior to joining MD Anderson, Dr. Shaw spent four years with The Cancer Genome Atlas (TCGA), a flagship project of the National Cancer Institute focused on accelerating understanding of the molecular basis of cancer. Dr. Shaw earned undergraduate degrees in Spanish and Biology at the College of William and Mary, and completed her doctoral degree in cell and developmental biology at Harvard University.
Precision Oncology Decision Support: Challenges & Opportunities
This talk will cover how challenges in biomarker testing in the cancer patient population are influencing progress, or lack thereof, in the implementation and promise of appropriate use of targeted, matched therapies in the cancer patient population. We will review current issues in the field and opportunities for improving options for patients and clinicians.
In addition to his current role, Edward S. Kim is Medical Director of the Clinical Trials Office and the Donald S. Kim Distinguished Chair for Cancer Research at the Levine Cancer Institute, Atrium Health in Charlotte, NC. Dr. Kim was previously at UT MD Anderson Cancer Center in Houston, Texas where he was a tenured Associate Professor of Medicine, Chief of the Section of Head and Neck Medical Oncology and Director of Clinical Research Operations in the Department of Thoracic/Head and Neck Medical Oncology. Dr Kim specializes in cancer biomarkers and novel targeted agents in the treatment and prevention settings and has expertise in lung, head and neck cancers. He chaired the Department of Defense Biomarker-based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) personalized medicine program in lung cancer. He currently oversees the solid tumor faculty and research development at Levine Cancer Institute. Dr Kim is the author or coauthor of more than 100 published articles, book chapters, reviews in journals such as Lancet, Lancet Oncology, Journal of Clinical Oncology, Cancer Discovery, Clinical Cancer Research Cancer, and Cancer Prevention Research, involving cancer therapeutics and prevention with chemotherapy and novel targeted agents, with particular emphases on lung cancer and head and neck cancer.
Rob’s responsibilities include identifying business opportunities to leverage a growing longitudinal clinical-genomic database for use in multiple healthcare channels. Prior to joining CTCA, Rob held 2 roles at ASCO including Senior Director of External Relations and Business Development for CancerLinQ and Senior Director of Quality Department and directed a large staff responsible for development of oncology quality measures, ASCO Guidelines, QOPI, QOPI Certification Program, and the development of the CancerLinQ program. In his 25 year career, Rob has led over 30 research activities, built businesses from idea to sale, and accumulated significant experience in business development, health economic and strategy planning services, clinical trial development, oncology registries, EMR systems, and informatics. He has served in roles as VP of Operations and Informatics while at International Oncology Network, and six years as VP and COO at Geriatric Oncology Consortium. He also spent two years with the research/consulting firm Abt Associates.